Stockscreener 앱 받기
4.45
4.01%
0.21
전일 마감가:
$4.24
열려 있는:
$4.28
하루 거래량:
41,258
Relative Volume:
0.19
시가총액:
$136.03M
수익:
$71.61M
순이익/손실:
$-48.59M
주가수익비율:
-2.5414
EPS:
-1.751
순현금흐름:
$-32.88M
1주 성능:
+4.26%
1개월 성능:
+13.08%
6개월 성능:
+29.71%
1년 성능:
-52.12%
1일 변동 폭
$4.28
$4.42
1주일 범위
$4.175
$4.565
52주 변동 폭
$3.22
$9.845
Avita Medical Inc Stock (RCEL) Company Profile
명칭
Avita Medical Inc
전화
661-568-1317
주소
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.42 | 130.49M | 71.61M | -48.59M | -32.88M | -1.751 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
296.67 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
78.22 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.48 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.14 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Northland Capital | Outperform |
| 2025-11-20 | 업그레이드 | BTIG Research | Sell → Neutral |
| 2025-08-08 | 다운그레이드 | BTIG Research | Neutral → Sell |
| 2024-12-24 | 개시 | D. Boral Capital | Buy |
| 2024-04-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-06-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-02 | 개시 | Piper Sandler | Overweight |
| 2020-08-27 | 개시 | BofA Securities | Buy |
| 2020-04-21 | 개시 | Oppenheimer | Outperform |
| 2020-03-03 | 개시 | BTIG Research | Buy |
모두보기
Avita Medical Inc 주식(RCEL)의 최신 뉴스
AVITA Medical appoints Cary Vance as permanent CEO - MSN
AVITA Medical Appoints Cary Vance as Permanent CEO and Jan Stern Reed as Board Chair to Drive Growth in Acute Wound Care Solutions - Minichart
Avita Medical (NASDAQ:RCEL) Stock Rating Lowered by Wall Street Zen - MarketBeat
AVITA Medical wins BARDA contract worth up to $25.5M - MSN
Avita Medical Names Cary Vance Permanent CEO, Reshapes Board - TipRanks
Cary Vance becomes AVITA Medical (NASDAQ: RCEL) CEO as Board elevates Jan Stern Reed to Chair - Stock Titan
AVITA Medical Names Cary Vance as Chief Executive Officer - Investing News Network
AVITA Medical names Cary Vance as permanent CEO - Investing.com
AVITA Medical names Cary Vance as permanent CEO By Investing.com - Investing.com Canada
After 6 months as interim CEO, Cary Vance gets AVITA's top job - Stock Titan
RCEL Stock Price, Quote & Chart | AVITA MEDICAL INC (NASDAQ:RCEL) - ChartMill
Avita Medical (RCEL) Secures Certification for Recell Go in Aust - GuruFocus
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO - Investing News Network
AVITA Medical gains regulatory clearance for RECELL GO in Australia By Investing.com - Investing.com Canada
Burn care tool cleared for sale in Australia and New Zealand - Stock Titan
Why this ASX healthcare stock is surging while the market sinks on Middle East fears - MSN
AVITA Medical appoints Cary Vance as interim CEO - MSN
Avita Medical (RCEL) upgraded to buy: Here's what you should know - MSN
Avita signals revenue recovery with $70M–$74M 2025 outlook following reimbursement clarity - MSN
AVITA Medical to Announce First Quarter 2026 Financial Results - Investing News Network
AVITA Medical schedules May 14 earnings release, 1:30 p.m. call - Stock Titan
Guess which ASX All Ords healthcare share is jumping 11% on big European news - MSN
Is Avita Medical (RCEL) stock under bearish pressure | Q4 2025: Below ExpectationsCyclicality - Cổng thông tin điện tử tỉnh Tây Ninh
Board pay, director equity and warrants on AVITA Medical (NASDAQ: RCEL) 2026 ballot - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc.RCEL - ChartMill
Is Avita Medical (RCEL) stock overpriced relative to performance (Trades Higher) 2026-04-18 - Cổng thông tin điện tử Tỉnh Sơn La
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $5.5 - 富途牛牛
ALERT: Price-sensitive ASX Announcement for AVH - intelligentinvestor.com.au
Avita Medical Inc (RCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
0.72%
자본화:
|
볼륨(24시간):